TIME-COURSE OF TOXICITY OF REACTIVE SULFONAMIDE METABOLITES

被引:43
作者
RIEDER, MJ
KRAUSE, R
BIRD, IA
机构
[1] UNIV WESTERN ONTARIO,CHILD HLTH RES INST,JP ROBARTS RES INST,DEPT PAEDIAT,LONDON,ON,CANADA
[2] UNIV WESTERN ONTARIO,CHILD HLTH RES INST,JP ROBARTS RES INST,DEPT PHARMACOL & TOXICOL,LONDON,ON,CANADA
关键词
SULFONAMIDES; HYDROXYLAMINES; ADVERSE DRUG REACTIONS;
D O I
10.1016/0300-483X(94)02900-F
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It has been suggested, on the basis of work in cell-free systems, that sulfonamide hydroxylamines are metabolized to nitroso metabolites which may be the proximate toxins mediating sulfonamide hypersensitivity reactions. We performed time-course experiments investigating the toxicity of the hydroxylamine and nitroso derivatives of sulfamethoxazole to investigate this hypothesis. The nitroso derivative of sulfamethoxazole was significantly more toxic than the hydroxylamine derivative (P < 0.05). When the LC(50) was compared over time, there was a significant decrease in the LC(50) of the hydroxylamine of sulfamethoxazole over time, while there was no change in the LC(50) of the nitroso derivative. There was an equivalent reduction in toxicity demonstrated when the hydroxylamine or nitroso derivatives were co-incubated with glutathione. This supports the role of the nitroso as a proximate toxin mediating sulfonamide hypersensitivity reactions and suggests an explanation for the high rate of adverse reactions to sulfonamides among patients with AIDS.
引用
收藏
页码:141 / 146
页数:6
相关论文
共 29 条
[1]  
CRIBB AE, 1991, DRUG METAB DISPOS, V19, P900
[2]  
CRIBB AE, 1990, DRUG METAB DISPOS, V18, P784
[3]   MANAGEMENT OF DRUG ALLERGY IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
GREENBERGER, PA ;
PATTERSON, R .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1987, 79 (03) :484-488
[4]  
LEEDER JS, 1991, BIOCHEM PHARMACOL, V41, P575
[5]   FLUORESCENCE-BASED VIABILITY ASSAY FOR STUDIES OF REACTIVE DRUG INTERMEDIATES [J].
LEEDER, JS ;
DOSCH, HM ;
HARPER, PA ;
LAM, P ;
SPIELBERG, SP .
ANALYTICAL BIOCHEMISTRY, 1989, 177 (02) :364-372
[6]  
MILLER EC, 1981, CANCER-AM CANCER SOC, V47, P2327, DOI 10.1002/1097-0142(19810515)47:10<2327::AID-CNCR2820471003>3.0.CO
[7]  
2-Z
[8]  
Mitchell J. R., 1984, DRUG METABOLISM DRUG, P301
[9]  
PARK BK, 1987, BIOCHEM PHARMACOL, V36, P581
[10]  
REED MD, 1988, ANTIMICROBIAL THERAP, P153